SCAI slides: Resolute at 3 years in patients with diabetes

Candace Stuart | | Cardiovascular Business | Interventional Cardiology

Kimberly A. Skelding, MD, of Geisinger Medical Center in Danville, Pa., presented three-year results of patients with diabetes mellitus who were enrolled in the Resolute U.S. trial at the Society of Cardiovascular Angiography and Interventions (SCAI) scientific sessions in Orlando, Fla.

The post-hoc analysis of patients treated with the Resolute drug-eluting stent for coronary artery disease found low rates of target lesion failure (10.8 percent in the diabetic subgroup) and target lesion revascularization (6.7 percent) and no stent thrombosis at three years. The researchers defined target lesion failure as cardiac death, target vessel MI and target lesion revascularization.

 

Skelding is director of Cardiovascular Genomics and Cardiovascular Research at the Geisinger Center for Health Research.

Candace Stuart, Contributor

Related Content

Surgery outperforms PCI in NSTEMI patients with multivessel CAD
Boston Scientific enters IVL arms race with acquisition worth up to $664M
FDA sees value in no-implant heart failure device
Radial secondary access during TAVR limits complications
Medtronic’s Harmony TPVR system gains CE mark approval
History made: Young child treated with new heart device for very first time

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.